Author

Shih‐Shih Chen

Northwell HealthORCID 0000-0001-6258-1750Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2

Frequent Co-Authors

Christoph SchultheißiD· 2 shared Heinz Philipp LaubliiD· 2 shared Lukas Egli· 2 shared Mascha BinderiD· 2 shared Nicholas ChiorazziiD· 2 shared Obinna ChijiokeiD· 2 shared Sebastian KoboldiD· 2 shared Andreas ZinggiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Christoph SchultheißORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyHaematologicaPeer-reviewedSep 11, 2025

IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia

Claudia Fischer, Shih‐Shih Chen, Johanna Nimmerfroh…·Mascha Binder

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

1 citation

humanproteomics

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedFeb 2, 2024

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

Florian Märkl, Christoph Schultheiß, Murtaza Ali…·Mascha Binder

This study develops CAR T cells targeting a specific mutation in CLL to selectively kill cancer cells while sparing healthy B cells.

15 citations

humanproteomics

𝕏 PostBluesky